DVAX · As filed with the SEC

Dynavax Technologies balance sheet, by quarter

The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Balance Sheets · USD thousands

USD thousandsQ3 2025
Sep 30, 2025
Q2 2025
Jun 30, 2025
Q1 2025
Mar 31, 2025
Q4 2024
Dec 31, 2024
Q3 2024
Sep 30, 2024
Q4 2023
Dec 31, 2023
Assets
Current assets:
Cash and cash equivalents160,24799,10151,72095,883119,332150,279
Marketable securities available-for-sale487,568514,628609,616617,951644,660592,023
Accounts receivables, net of allowance for doubtful accounts of $0 and $12,313 at September 30, 2025 and December 31, 2024, respectively72,35970,69954,92545,28173,33440,607
Other receivables9622,6461,6321,6251,9433,926
Inventories73,28875,68774,40370,05462,40253,290
Prepaid expenses and other current assets19,90722,95123,67418,14724,57018,995
Total current assets814,331785,712815,970848,941926,241859,120
Property and equipment, net45,85545,61043,27239,00137,42037,297
Operating lease right-of-use assets19,90420,31420,86921,60821,78024,287
Goodwill2,1992,2002,0271,9462,0912,067
Other assets, net of allowance for doubtful accounts of $10,970 at September 30, 202564,21764,61363,79074,76074,45874,325
Total assets946,506918,449945,928986,2561,061,990997,096
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable3,9482,7024,3309,0617,0895,245
Accrued research and development6,6975,4595,6544,3104,4022,982
CEPI accrual (Note 9)—————0
Accrued liabilities51,88965,95254,29261,06654,10249,448
Convertible Notes, current portion, net of debt discount of $135 at September 30, 2025 (Note 7)40,07340,020————
Other current liabilities4,2324,0974,1034,1974,4374,520
Total current liabilities106,839118,23068,37978,63470,03062,195
Convertible Notes, net of debt discount of $4,701 and $1,646 at March 31, 2025 and December 31, 2024, respectively (Note 7)——260,507223,854223,561222,698
Convertible Notes, net of debt discount of $4,034 and $1,646 at September 30, 2025 and December 31, 2024, respectively (Note 7)220,966220,752————
Long-term portion of lease liabilities23,98524,72625,52126,38826,60729,720
CEPI accrual long-term (Note 6)60,33760,33760,33760,33760,33760,337
Other long-term liabilities2412422432442874
Total liabilities412,368424,287414,987389,457380,563375,024
Stockholders’ equity:
Preferred stock: $0.001 par value, 5,000 shares authorized at September 30, 2025 and December 31, 2024; zero shares outstanding at September 30, 2025 and December 31, 2024000000
Common stock: $0.001 par value, 278,000 shares authorized at September 30, 2025 and December 31, 2024; 117,364 shares and 125,450 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively117117124125131130
Additional paid-in capital1,486,9471,474,0461,532,8351,504,6711,591,1071,554,634
Accumulated other comprehensive income800652(2,644)(4,722)514(2,108)
Accumulated deficit(953,726)(980,653)(999,374)(903,275)(910,325)(930,584)
Total stockholders’ equity534,138494,162530,941596,799681,427622,072
Total liabilities and stockholders’ equity946,506918,449945,928986,2561,061,990997,096

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.